These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3904417)

  • 41. Simultaneous occurrence of acute myeloblastic leukaemia and multiple myeloma without previous chemotherapy.
    Tursz T; Flandrin G; Brouet JC; Briere J; Seligmann M
    Br Med J; 1974 Jun; 2(5920):642-3. PubMed ID: 4600910
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid detection of S-phase cells by anti-bromodeoxyuridine monoclonal antibody in 9L brain tumor cells in vitro and in situ.
    Nagashima T; Hoshino T
    Acta Neuropathol; 1985; 66(1):12-7. PubMed ID: 3993331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
    Bueno C; Lopes LF; Greaves M; Menendez P
    Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665
    [No Abstract]   [Full Text] [Related]  

  • 44. Vacuolated plasma cells in multiple myeloma.
    Kanoh T; Yasuda N; Takamatsu T; Uchino H
    Tohoku J Exp Med; 1986 Apr; 148(4):361-4. PubMed ID: 3526637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma cell labeling index.
    Greipp PR; Kumar S
    Methods Mol Med; 2005; 113():25-35. PubMed ID: 15968092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunoglobulin gene rearrangement in multiple myeloma: limitations of Southern blot analysis.
    Humphries JE; Dressman HK; Williams ME
    Hum Pathol; 1991 Oct; 22(10):966-71. PubMed ID: 1842385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone marrow plasma cell infiltration in multiple myeloma.
    de Gramont A; Benitez O; Smadja N; Brissaud P; Sirinelli A; Hubert D; Krulik M; Debray J
    Br J Haematol; 1984 Jun; 57(2):351-3. PubMed ID: 6733051
    [No Abstract]   [Full Text] [Related]  

  • 48. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
    Pasqualetti P; Colantonio D; Casale R
    Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging.
    Bartl R; Frisch B; Burkhardt R; Fateh-Moghadam A; Mahl G; Gierster P; Sund M; Kettner G
    Br J Haematol; 1982 Jul; 51(3):361-75. PubMed ID: 7104223
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double labeling and in vitro versus in vivo incorporation of bromodeoxyuridine in patients with acute nonlymphocytic leukemia.
    Raza A; Ucar K; Preisler HD
    Cytometry; 1985 Nov; 6(6):633-40. PubMed ID: 3905302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth kinetics of plasma cell myeloma.
    Drewinko B; Alexanian R
    J Natl Cancer Inst; 1977 May; 58(5):1247-53. PubMed ID: 857025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Colony growth and self renewal of plasma cell precursors in multiple myeloma.
    Takahashi T; Lim B; Jamal N; Tritchler D; Lockwood G; McKinney S; Bergsagel DE; Messner HA
    J Clin Oncol; 1985 Dec; 3(12):1613-23. PubMed ID: 4067612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonsecretory myeloma. Immunofluorescent demonstration of paraprotein within bone marrow plasma cells.
    Arend WP; Adamson JW
    Cancer; 1974 Mar; 33(3):721-8. PubMed ID: 4131359
    [No Abstract]   [Full Text] [Related]  

  • 54. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conventional diagnostics in multiple myeloma.
    San Miguel JF; Gutiérrez NC; Mateo G; Orfao A
    Eur J Cancer; 2006 Jul; 42(11):1510-9. PubMed ID: 16762540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma].
    Schleiffenbaum BE
    Praxis (Bern 1994); 2012 Nov; 101(24):1521-9; quiz 1530-1. PubMed ID: 23184544
    [No Abstract]   [Full Text] [Related]  

  • 57. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.
    Boccadoro M; Marmont F; Tribalto M; Fossati G; Redoglia V; Battaglio S; Massaia M; Gallamini A; Comotti B; Barbui T
    J Clin Oncol; 1989 Jan; 7(1):119-25. PubMed ID: 2909664
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.
    Tong AW; Lee J; Wang RM; Dalton WS; Tsuruo T; Fay JW; Stone MJ
    Cancer Res; 1989 Sep; 49(17):4829-34. PubMed ID: 2569359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.
    Alley CL; Wang E; Dunphy CH; Gong JZ; Lu CM; Boswell EL; Burchette J; Lagoo AS
    Arch Pathol Lab Med; 2013 Apr; 137(4):503-17. PubMed ID: 23544940
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple myeloma with monoclonal surface immunoglobulin expression: a case report.
    Dunphy CH; Galindo LM; Velasquez WS
    Acta Cytol; 1996; 40(2):358-62. PubMed ID: 8629427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.